Experts say this week in January, shortly after the dawn of a new year, is always the busiest time for new inquiries and ...
CAPLYTA® nearly doubled the likelihood of remission at six weeks compared to placebo as an adjunctive therapy to an antidepressant based on pooled data ...
AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results